Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Kedudukan dalam Saham #32454
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Harga Saham
$1.11
Disegerakkan terakhir: 2026-08-17
Modal Pasaran
$10.06M
Perubahan (1 hari)
1.38%
Perubahan (1 tahun)
-55.98%
Negara
US
Perdagangan Lisata Therapeutics, Inc. (LSTA)

Kategori

Nisbah P/S bagi Lisata Therapeutics, Inc. (LSTA)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Lisata Therapeutics, Inc., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Lisata Therapeutics, Inc. dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
- -
KR